Pediatrix Medical Group (NYSE:MD) Director Sells $240,994.00 in Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Michael Rucker sold 10,478 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the sale, the director owned 59,101 shares of the company’s stock, valued at approximately $1,359,323. The trade was a 15.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pediatrix Medical Group Stock Performance

Shares of Pediatrix Medical Group stock traded down $0.06 during trading hours on Wednesday, reaching $22.91. The company’s stock had a trading volume of 840,843 shares, compared to its average volume of 783,477. Pediatrix Medical Group, Inc. has a one year low of $11.84 and a one year high of $23.43. The company’s 50 day simple moving average is $18.11 and its 200 day simple moving average is $15.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.80 and a current ratio of 1.80. The stock has a market cap of $1.97 billion, a P/E ratio of 17.76 and a beta of 1.20.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The firm had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. During the same quarter in the prior year, the business earned $0.44 earnings per share. Pediatrix Medical Group’s quarterly revenue was down 3.6% on a year-over-year basis. As a group, analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on MD. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Thursday, November 13th. Leerink Partners raised their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. Truist Financial boosted their price target on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, UBS Group lifted their price objective on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $21.00.

Institutional Investors Weigh In On Pediatrix Medical Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. increased its stake in Pediatrix Medical Group by 30.7% during the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after buying an additional 968,553 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Pediatrix Medical Group by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,399,778 shares of the company’s stock worth $56,942,000 after acquiring an additional 81,554 shares during the period. American Century Companies Inc. boosted its holdings in shares of Pediatrix Medical Group by 38.9% in the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after acquiring an additional 751,109 shares in the last quarter. Boston Partners increased its stake in shares of Pediatrix Medical Group by 1.3% during the first quarter. Boston Partners now owns 1,981,889 shares of the company’s stock valued at $27,990,000 after acquiring an additional 25,536 shares during the period. Finally, Qube Research & Technologies Ltd raised its holdings in Pediatrix Medical Group by 55.4% during the third quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock worth $19,150,000 after purchasing an additional 407,780 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.